These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

139 related items for PubMed ID: 17924396

  • 21. Liposomal vasoactive intestinal peptide.
    Sethi V, Onyüksel H, Rubinstein I.
    Methods Enzymol; 2005; 391():377-95. PubMed ID: 15721392
    [Abstract] [Full Text] [Related]

  • 22. Differential expression of vasoactive intestinal peptide and its functional receptors in human osteoarthritic and rheumatoid synovial fibroblasts.
    Juarranz Y, Gutiérrez-Cañas I, Santiago B, Carrión M, Pablos JL, Gomariz RP.
    Arthritis Rheum; 2008 Apr; 58(4):1086-95. PubMed ID: 18383383
    [Abstract] [Full Text] [Related]

  • 23. Identification of key residues that cause differential gallbladder response to PACAP and VIP in the guinea pig.
    Wei M, Fujiki K, Ando E, Zhang S, Ozaki T, Ishiguro H, Kondo T, Nokihara K, Wray V, Naruse S.
    Am J Physiol Gastrointest Liver Physiol; 2007 Jan; 292(1):G76-83. PubMed ID: 16901992
    [Abstract] [Full Text] [Related]

  • 24. Novel vasoactive intestinal peptide derivatives with improved stability protect rat alveolar L2 cells from cigarette smoke-induced cytotoxicity and apoptosis.
    Misaka S, Sato H, Aoki Y, Mizumoto T, Onoue S, Yamada S.
    Peptides; 2011 Feb; 32(2):401-7. PubMed ID: 20977915
    [Abstract] [Full Text] [Related]

  • 25. Vasoactive intestinal peptide inhibits toll-like receptor 3-induced nitric oxide production in Schwann cells and subsequent sensory neuronal cell death in vitro.
    Lee H, Park K, Kim JS, Lee SJ.
    J Neurosci Res; 2009 Jan; 87(1):171-8. PubMed ID: 18683246
    [Abstract] [Full Text] [Related]

  • 26. Stabilization of vasoactive intestinal peptide by lipids.
    Gololobov G, Noda Y, Sherman S, Rubinstein I, Baranowska-Kortylewicz J, Paul S.
    J Pharmacol Exp Ther; 1998 May; 285(2):753-8. PubMed ID: 9580623
    [Abstract] [Full Text] [Related]

  • 27. Glyco-scan: varying glycosylation in the sequence of the peptide hormone PYY3-36 and its effect on receptor selectivity.
    Pedersen SL, Steentoft C, Vrang N, Jensen KJ.
    Chembiochem; 2010 Feb 15; 11(3):366-74. PubMed ID: 20049760
    [Abstract] [Full Text] [Related]

  • 28. Chemoenzymatic synthesis of glycosylated glucagon-like peptide 1: effect of glycosylation on proteolytic resistance and in vivo blood glucose-lowering activity.
    Ueda T, Tomita K, Notsu Y, Ito T, Fumoto M, Takakura T, Nagatome H, Takimoto A, Mihara S, Togame H, Kawamoto K, Iwasaki T, Asakura K, Oshima T, Hanasaki K, Nishimura S, Kondo H.
    J Am Chem Soc; 2009 May 06; 131(17):6237-45. PubMed ID: 19361194
    [Abstract] [Full Text] [Related]

  • 29. Assessment of the conformational features of vasoactive intestinal peptide in solution by limited proteolysis experiments.
    Stiuso P, Marabotti A, Facchiano A, Lepretti M, Dicitore A, Ferranti P, Cartenì M.
    Biopolymers; 2006 Feb 05; 81(2):110-9. PubMed ID: 16224772
    [Abstract] [Full Text] [Related]

  • 30. Synthesis of a hydrophilic affinity matrix for the purification of the vasoactive intestinal peptide receptor.
    Fournier A, Couvineau A, Laburthe M.
    Anal Biochem; 1993 Jun 05; 211(2):305-10. PubMed ID: 8391225
    [Abstract] [Full Text] [Related]

  • 31. cAMP activation by PACAP/VIP stimulates IL-6 release and inhibits osteoblastic differentiation through VPAC2 receptor in osteoblastic MC3T3 cells.
    Nagata A, Tanaka T, Minezawa A, Poyurovsky M, Mayama T, Suzuki S, Hashimoto N, Yoshida T, Suyama K, Miyata A, Hosokawa H, Nakayama T, Tatsuno I.
    J Cell Physiol; 2009 Oct 05; 221(1):75-83. PubMed ID: 19496170
    [Abstract] [Full Text] [Related]

  • 32. Comparative efficacy of VIP and analogs on activation and internalization of the recombinant VPAC2 receptor expressed in CHO cells.
    Langlet C, Gaspard N, Nachtergael I, Robberecht P, Langer I.
    Peptides; 2004 Dec 05; 25(12):2079-86. PubMed ID: 15572195
    [Abstract] [Full Text] [Related]

  • 33. Alpha-helical structure in the C-terminus of vasoactive intestinal peptide: functional and structural consequences.
    Onoue S, Matsumoto A, Nagano Y, Ohshima K, Ohmori Y, Yamada S, Kimura R, Yajima T, Kashimoto K.
    Eur J Pharmacol; 2004 Feb 06; 485(1-3):307-16. PubMed ID: 14757155
    [Abstract] [Full Text] [Related]

  • 34. Vasoactive intestinal polypeptide (VIP) and VPAC1 receptor in adult human dental pulp in relation to caries.
    El Karim IA, Lamey PJ, Ardill J, Linden GJ, Lundy FT.
    Arch Oral Biol; 2006 Oct 06; 51(10):849-55. PubMed ID: 16806045
    [Abstract] [Full Text] [Related]

  • 35. Structure-activity studies of vasoactive intestinal peptide (VIP): cyclic disulfide analogs.
    Bolin DR, Cottrell J, Garippa R, O'Neill N, Simko B, O'Donnell M.
    Int J Pept Protein Res; 1993 Feb 06; 41(2):124-32. PubMed ID: 8384606
    [Abstract] [Full Text] [Related]

  • 36. The development of VIP-ellipticine conjugates.
    Moody TW, Czerwinski G, Tarasova NI, Moody DL, Michejda CJ.
    Regul Pept; 2004 Dec 15; 123(1-3):187-92. PubMed ID: 15518911
    [Abstract] [Full Text] [Related]

  • 37. In silico classification and prediction of VIP derivatives as VPAC1/ VPAC2 receptor agonists/antagonists.
    Li J, Wang X, Liu H, Li H.
    Comb Chem High Throughput Screen; 2015 Dec 15; 18(1):33-41. PubMed ID: 25438751
    [Abstract] [Full Text] [Related]

  • 38. Physicochemical and pharmacological characterization of novel vasoactive intestinal peptide derivatives with improved stability.
    Onoue S, Misaka S, Ohmori Y, Sato H, Mizumoto T, Hirose M, Iwasa S, Yajima T, Yamada S.
    Eur J Pharm Biopharm; 2009 Sep 15; 73(1):95-101. PubMed ID: 19481602
    [Abstract] [Full Text] [Related]

  • 39. N-linked glycosylated beta-peptides are resistant to degradation by glycoamidase A.
    Disney MD, Hook DF, Namoto K, Seeberger PH, Seebach D.
    Chem Biodivers; 2005 Dec 15; 2(12):1624-34. PubMed ID: 17191959
    [Abstract] [Full Text] [Related]

  • 40. Class II G protein-coupled receptors for VIP and PACAP: structure, models of activation and pharmacology.
    Laburthe M, Couvineau A, Tan V.
    Peptides; 2007 Sep 15; 28(9):1631-9. PubMed ID: 17574305
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 7.